BATS · FLXN
Financial Services · Asset Management
$24.93
Down-$0.01 (-0.04%)
Updated Aug 24, 2026, 9:14 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
FLXN closed at $24.93 after 20 trading sessions, up 1.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $24.96 | $24.96 | $24.91 | $24.9301 | 7.61K |
| Aug 20, 2026 | $24.895 | $24.9296 | $24.8701 | $24.90 | 4.35K |
| Aug 19, 2026 | $24.94 | $25.00 | $24.93 | $24.955 | 15.13K |
| Aug 18, 2026 | $24.88 | $24.91 | $24.85 | $24.8802 | 4.88K |
| Aug 17, 2026 | $24.91 | $24.97 | $24.91 | $24.9201 | 9.54K |
| Aug 14, 2026 | $25.0052 | $25.0052 | $24.92 | $24.9501 | 7.98K |
| Aug 13, 2026 | $24.985 | $25.00 | $24.94 | $24.9701 | 5.69K |
| Aug 12, 2026 | $24.91 | $24.95 | $24.89 | $24.92 | 6.21K |
| Aug 11, 2026 | $24.95 | $24.95 | $24.86 | $24.885 | 6.95K |
| Aug 10, 2026 | $24.93 | $24.93 | $24.86 | $24.8652 | 7.83K |
| Aug 7, 2026 | $24.915 | $24.94 | $24.885 | $24.9052 | 7.29K |
| Aug 6, 2026 | $24.87 | $24.89 | $24.83 | $24.86 | 3.1K |
| Aug 5, 2026 | $24.85 | $24.90 | $24.8475 | $24.8733 | 7.07K |
| Aug 4, 2026 | $24.875 | $24.93 | $24.87 | $24.8998 | 8.88K |
| Aug 3, 2026 | $24.82 | $24.82 | $24.7603 | $24.8005 | 4.61K |
| Jul 31, 2026 | $24.69 | $24.75 | $24.66 | $24.7155 | 1.19M |
| Jul 30, 2026 | $24.67 | $24.7087 | $24.67 | $24.695 | 2.8K |
| Jul 29, 2026 | $24.55 | $24.655 | $24.5303 | $24.5303 | 2.79K |
| Jul 28, 2026 | $24.63 | $24.67 | $24.62 | $24.6451 | 2.53K |
| Jul 27, 2026 | $24.585 | $24.60 | $24.56 | $24.60 | 2.27K |
The latest Smart Investors Daily articles mentioning FLXN.
FLXN research
Company profile and research snapshot.
An actively managed fixed-income ETF focusing primarily on high-yield (non-investment-grade) bonds with dynamic exposure shifts and options overlays (e.g., put spreads, collars) for current income and risk management
Consensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 19, 2021 | Northland Capital Markets | Market Perform | — |
| Oct 19, 2021 | HC Wainwright & Co. | Neutral | — |
| Oct 12, 2021 | BMO Capital | Market Perform | — |
| Oct 12, 2021 | Credit Suisse | Neutral | — |
| Oct 12, 2021 | Raymond James | Market Perform | — |
No generated briefing is available yet.
Zacks Investment Research · Nov 3, 2021
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Zacks Investment Research · Oct 27, 2021
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research · Oct 12, 2021
Slow Start to Busy Week of Inflation Data and Earnings
GlobeNewswire Inc. · Oct 11, 2021
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FLXN.
